Milestone Scientific, a leading developer of computerised drug delivery instruments that provide objective, pressure-guided precision, announced the launch of the CompuFlo Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimise long-term Medicare reimbursement rates.
The program, which commenced on February 1, 2026, targets high-volume interventional pain and anaesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian, and Palmetto. These jurisdictions represent a strategic first phase of execution, with infrastructure designed to support phased expansion across additional MAC regions throughout the United States. By engaging Key Opinion Leaders (KOLs) to generate a targeted 1,000–2,000 case submissions in the initial six-month phase, Milestone is executing a structured clinical and reimbursement roadmap to transition CPT® code 0777T from Category III to Category I status, which could enhance commercial adoption and long-term revenue visibility.
To ensure the program delivers a scalable recurring revenue model, Milestone has deployed a robust commercial infrastructure designed to support national expansion. The Company has also engaged industry veterans, including Evelyn Gittinger, CPC, and Neuro Management Solutions (NMS), to provide real-time claims support, documentation guidance, and payer advocacy.
"The Advisor Program is a key strategic initiative for Milestone Scientific this year," stated Eric Hines, CEO of Milestone Scientific. "We have moved beyond simply placing devices to building a comprehensive commercial ecosystem. We are deploying a 'white glove' support infrastructure, including veteran consultants and a dedicated provider hotline, to support our physicians through every step of the reimbursement process. With favourable unit economics and a scalable model, we believe establishing reimbursement with this initial cohort will unlock a recurring revenue flywheel that can be rapidly expanded to hundreds of physicians nationwide."
